Circle Pharma vs Neuralink

Side-by-side comparison of AI visibility scores, market position, and capabilities

Circle Pharma logo

Circle Pharma

NicheLife Sciences & BioTech

Cell-Permeable Macrocycle Oncology Therapeutics

Circle Pharma develops orally deliverable macrocycle drug candidates targeting intracellular protein-protein interactions in cancer; raised $90M Series B in 2023 led by Novo Holdings and Foresite Capital; headquartered in San Francisco;

About

Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is developing a new class of therapeutics — cell-permeable macrocycles — designed to inhibit intracellular protein-protein interactions (PPIs) that have historically been considered "undruggable." Protein-protein interactions control critical cellular processes including cell division, apoptosis (programmed cell death), and gene expression. Dysregulation of these interactions drives many cancers, but their large, flat interaction surfaces are difficult to block with small molecules, and biologics (antibodies) cannot cross cell membranes to reach intracellular targets. Circle Pharma's macrocycles are medium-sized ring-shaped molecules engineered to be both cell-permeable and orally bioavailable — a combination rarely achieved — enabling them to reach and inhibit these targets.

Full profile
Neuralink logo

Neuralink

LeaderLife Sciences & BioTech

Brain-Computer Interface

Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.

About

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.

Full profile

Key Details

Category
Cell-Permeable Macrocycle Oncology Therapeutics
Brain-Computer Interface
Tier
Niche
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.